Background <p>Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an…
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Journal for ImmunoTherapy of Cancer | | Li, C., Madan, R. A., Lee, M.-J., Lee, S., Sato, N., Rastogi, S., Shrestha, R., Aragon-Ching, J. B., Goswami, M., Donahue, R. N., Cordes, L. M., Baj, A., Seo, C. C. Y., Terrigino, N. T., Bright, J. R., Hennigan, S. T., King, I. M., Trostel, S. Y., Fenimore, J. M., Liu, Y., Calzone, K. A., Schlom, J., Gulley, J. L., Dahut, W. L., Figg, W. D., Sowalsky, A. G., Lee, J.-M., Karzai, F.
Topics: prostate-cancer, cervical-cancer, immunotherapy, targeted-therapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer